Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Warma says CAR-T can only target extracellular antigens, limiting it to less than 3% of cancer patients. Mongoose Bio's TCR T-cell approach, from Cassian Yi at MD Anderson, goes after novel intracellular targets expressed on solid tumors. He says this opens treatment to patients who currently lack CAR-T options.

Related Insights

To overcome the industry bottleneck of few validated solid tumor targets (15-20), Memo analyzes tumor-infiltrating B-cells from patients with superior outcomes. This approach aims to identify unique antibody-target pairs, unlocking new biological pathways for next-generation therapies like ADCs and CAR-Ts.

The success of early CAR-T cell therapies was partly luck. Future therapies face a high bar, as an ideal target must meet three criteria: 1) be abundant on cancer cells, 2) be indispensable for the cancer's survival, and 3) be dispensable for the patient's healthy tissues to avoid lethal toxicity.

While revolutionary for liquid tumors, CAR-T cells struggle to attack solid tumors. The tumor's 'microenvironment'—a complex ecosystem of blood vessels, immune cells, and supportive structures—acts as a physical and biological barrier that prevents the engineered T-cells from reaching their target.

T-cell receptor (TCR) therapies offer a significant advantage over monoclonal antibodies by targeting intracellular proteins. They recognize peptides presented on the cell surface, effectively unlocking 90% of the proteome and requiring far fewer target molecules (5-10 copies vs. 1000+) to kill a cancer cell.

Developing CAR T-cell therapies for solid tumors is difficult because many tumor-associated antigens are also expressed on normal tissues. This creates a significant risk of "on-target, off-tumor" effects, causing severe toxicity. Mitigating this risk, for instance with engineered "kill switches," is as crucial as preserving the therapy's efficacy.

While CAR-T therapy is known in blood cancers, engineered T-cell receptor (TCR) therapies are finding their first major successes in solid tumors within the sarcoma community. Treatments targeting MAGE-A4 and NY-ESO-1 in specific sarcomas are demonstrating high efficacy and leading development in the field.

CAR-T cells are engineered to recognize a single antigen, which tumors can downregulate to escape. In contrast, TIL therapy uses a patient's own T-cells that naturally recognize multiple tumor antigens. This polyclonal attack creates a higher barrier for the cancer to develop resistance compared to a single-target CAR-T therapy.

Unlike antigen-directed therapies like CAR-T that can fail due to tumor heterogeneity, this MSC platform targets shared vulnerabilities across tumor subclones, such as DNA damage and immune suppression. This antigen-agnostic strategy is designed to be effective against diverse and evolving cancers.

Rather than expecting cell therapies (CAR-T, TIL) to eradicate every cancer cell, Dr. Radvanyi reframes them as powerful adjuvants. Their role is to inflict initial damage, kill tumor cells, and release antigens, creating an opportunity to prime a broader, secondary immune response with other modalities like vaccines or checkpoint inhibitors.

For solid tumors, the critical design hurdle for T-cell engagers is achieving selectivity. Most target antigens are also expressed at low levels on healthy cells, so molecules must be engineered to attack tumors with high antigen expression while sparing healthy tissue to avoid on-target, off-tumor toxicity.

CAR-T's extracellular limit leaves most cancers untreated | RiffOn